NEW YORK (GenomeWeb News) – Life Technologies officials said this week that the company has formed a licensing team that will focus on offsetting declining royalty revenues for its PCR-related intellectual property and other IP.

During a conference call to discuss the company's third-quarter financial results, Life Tech Chairman and CEO Greg Lucier said that the company has assembled a team of the "best licensing people" from its Applied Biosystems and Invitrogen businesses.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.